First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation
Christof Vulsteke(University of Antwerp), Paul M. Clément(Universitair Ziekenhuis Leuven), Maria Dêbiec‐Rychter(Center for Human Genetics), Jeroen Mebis(Jessa Hospital), Constantinus Politis(KU Leuven), Esther Hauben(Universitair Ziekenhuis Leuven), Eveline Lurquin(KU Leuven), Sandra Nuyts(Cancer Institute (WIA)), Joseph Schoenaers(KU Leuven), Olivier Gheysens(Cliniques Universitaires Saint-Luc)
Cited by 17
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines
|Journal of the National Comprehensive Cancer Network|2007|636
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573